08:07 AM EDT, 08/06/2024 (MT Newswires) -- Summit Therapeutics ( SMMT ) reported a Q2 non-GAAP net loss Tuesday of $0.05 per diluted share, widening from a loss of $0.02 a year earlier.

Two analysts polled by Capital IQ expected a loss of $0.06.

As expected, no revenue for the quarter ended June 30 was reported.

As of June 30, the clinical-stage drug discovery and development company said it had $325.8 million in cash, cash equivalents, restricted cash and short-term investments and expected it could fund operations into Q4 2025.

Price: 10.05, Change: +0.03, Percent Change: +0.35